Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2012 Sep 1.

Published in final edited form as: Biomaterials. 2011 Sep;32(26):6291–6301. doi: 10.1016/j.biomaterials.2011.05.024

Table 3.

Tumor targeting advantages (TA) of PEG-MNPs with respect to various benchmarks

Benchmark	D5 Advantage	D20 Advantage
Non-Targeted Self	5.0	5.5
Targeted D	12	15
Non-Targeted D	184	229